The US Congress may permanently place some synthetic drugs on Schedule I of the Controlled Substances Act (CSA). They include cannabinoids and stimulants such as methamphetamine, MDMA and “bath salts.” Complicating considerations are designer drugs, or synthetics with their structures altered to have the same effect as yet not be chemically similar to controlled substances—a […]
Of over 3,400 food-safety violations in 2013 connected to exported raw or minimally processed products from 117 countries, the three most common categories of food violating the inspecting countries’ regulations were seafood, vegetables and fruits, accounting for 24%, 20% and 14% of incidents, respectively. The top three countries of origin of the foods associated with […]
Washington, DC 8/29/14—Bio-Rad Laboratories stated in an SEC filing that Bradford J. Crutchfield, executive vice president and president of its Life Sciences Group, is no longer employed by the company, effective August 26. A replacement has yet to be named.
Montpellier, France 8/11/14 ; Paris, France 8/12/14—Alpha MOS, which filed for bankruptcy last year (see IBO 12/15/13), has announced that publicly held French company DMS, a provider of diagnostic medical-imaging systems, plans to make an investment in the company as part of a capital increase that will also include current shareholders. The offering will take […]
Paris, France 7/21/14; St. Ives, UK 7/22/14 —Environnement, a publicly held French provider of online environmental monitors, has acquired UK-based PCME for €8 million ($11 million = €0.74 = $1). PCME supplies continuous particulate monitors for industrial processes and had fiscal 2014 revenues of €10 million ($14 million). “The expertise of PCME for the monitoring […]
San Diego, CA 7/28/14—Independent service organization (ISO) Zef Scientific has filed suit against Shimadzu Scientific Instruments (SSI) in US District Court for the Southern District of California, alleging monopolization, restraint of trade, tortious interference with contractual relations, tortious interference with prospective business advantage, and unfair competition. In the complaint, Zef states that SSI changed its […]
San Diego, CA 8/21/14; London, England 8/21/14—Illumina has formed collaborative partnerships with AstraZeneca, Janssen Biotech and Sanofi to develop a universal next-generation sequencing (NGS)–based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multigene panel for therapeutic selection. The partnership involves […]
Calendar-year second quarter revenues for major, publicly held analytical instrument companies showed steady growth, despite purchase delays in China and uneven academic spending. Combined quarterly revenues for seven businesses whose quarterly results are profiled on pages 9–11 grew 4.8%, or 4.4% on an organic basis. Illumina recorded double-digit sales growth, while revenues for Bio-Rad Laboratories […]
As part of its move into the clinical market, Illumina has formed a collaboration with pharmaceutical companies AstraZeneca, Janssen Biotech and Sanofi to develop a companion-diagnostic test for oncology based on next-generation sequencing (NGS) (see page 2). Intending to extend the partnership to additional companies, Illumina plans to develop the Universal Oncology Test System, to […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
